EMERYVILLE, Calif., May 9 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health, is scheduled to present at Rodman & Renshaw’s 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Monday, May 14, 2007 at 8:40 a.m. (local time). Company co-founder and CEO, Isaac Cohen, will provide an overview and discuss the company’s drugs, technologies and collaborations.
Event: Bionovo Presentation at Rodman & Renshaw’s 4th Annual Global Healthcare Conference When: Monday, May 14th at 8:40 a.m. (Local Monte Carlo Time) Where: Le Meridien Beach Plaza Hotel Atlantique Salon -- Western Room Monte Carlo, Monaco
Additional information regarding the conference can be found at http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers, including the University of California, San Francisco, University of Colorado Health Sciences Center, and University of California, Berkeley. For further information, please visit: http://www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Company Contacts: BioNovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510-420-4180 jim@bionovo.com Media: Katherina Audley Phone: 415-847-7295 katherina.audley@bionovo.com
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer, BioNovo, Inc.,+1-510-420-4180, or jim@bionovo.com; or Katherina Audley, +1-415-847-7295,or katherina.audley@bionovo.com
Web site: http://www.bionovo.com//
